Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
26th October 2022 Uncategorised 0 Even as Revlimid’s star fades, Bristol Myers’ core offerings have reached a ‘critical mass,’ CEO says
fkansteiner
Wed, 10/26/2022 – 09:41
More: Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Source: fierce